NASDAQ:AMRN - Amarin Stock Price, News & Analysis

$15.66
+0.51 (+3.37 %)
(As of 08/20/2019 08:06 AM ET)
Today's Range
$15.20
Now: $15.66
$15.84
50-Day Range
$14.05
MA: $18.66
$23.16
52-Week Range
$2.65
Now: $15.66
$23.91
Volume8.23 million shs
Average Volume9.68 million shs
Market Capitalization$5.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.21 million
Book Value$0.40 per share

Profitability

Net Income$-116,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$5.59 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01. The biopharmaceutical company had revenue of $100.40 million for the quarter, compared to analyst estimates of $99.54 million. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. The company's revenue was up 90.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.10) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Amarin.

What guidance has Amarin issued on next quarter's earnings?

Amarin updated its second quarter 2019 earnings guidance on Tuesday, July, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97-101 million, compared to the consensus revenue estimate of $95.62 million.

What price target have analysts set for AMRN?

9 analysts have issued 1-year price targets for Amarin's stock. Their forecasts range from $20.00 to $51.00. On average, they expect Amarin's stock price to reach $31.1250 in the next year. This suggests a possible upside of 98.8% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on AMRN shares after the company reported its 2Q19 financials, which came in at the higher end of its 7/2 pre-announcement; however, the key update is the fact management announced it believes an adcom is unlikely for Vascepa’s sNDA now given the close proximity to its PDUFA date. As we have discussed in previous notes, we believed the lack of an adcom would further de-risk Vascepa’s sNDA – so we see this update as an incremental positive and gets us more confident in sNDA approval. Given the high probability of approval, we believe investor focus is shifting to: (1) how Vascepa’s expanded label will read; (2) commercial execution in 2020 given its planned sales force expansion and whether or not 2020 Vascepa consensus sales estimates are too low; and (3) the potential timing and outcomes of Vascepa’s ongoing ANDA litigation." (7/31/2019)
  • 3. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (7/24/2019)

Has Amarin been receiving favorable news coverage?

News headlines about AMRN stock have trended somewhat positive on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amarin earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Amarin.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Square (SQ), Alibaba Group (BABA), Exelixis (EXEL), AcelRx Pharmaceuticals (ACRX), Portola Pharmaceuticals (PTLA) and Gilead Sciences (gild).

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Invesco Ltd. (2.36%), Perceptive Advisors LLC (1.74%), Price T Rowe Associates Inc. MD (1.31%), Farallon Capital Management LLC (1.19%), BlackRock Inc. (0.92%) and EULAV Asset Management (0.53%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Perceptive Advisors LLC, Price T Rowe Associates Inc. MD, Cormorant Asset Management LP, Orbimed Advisors LLC, BlackRock Inc., Joseph P. Lucia & Associates LLC and DLD Asset Management LP. Company insiders that have sold Amarin company stock in the last year include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Farallon Capital Management LLC, Morgan Stanley, Kornitzer Capital Management Inc. KS, EULAV Asset Management and Bank of America Corp DE. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $15.66.

How big of a company is Amarin?

Amarin has a market capitalization of $5.59 billion and generates $229.21 million in revenue each year. The biopharmaceutical company earns $-116,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. View Additional Information About Amarin.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com/.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  668 (Vote Outperform)
Underperform Votes:  406 (Vote Underperform)
Total Votes:  1,074
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel